Literature DB >> 33099360

Clinical features, surgical treatment, and outcome of intracranial aneurysms associated with moyamoya disease.

Peicong Ge1, Xun Ye1, Qian Zhang1, Xingju Liu1, Xiaofeng Deng1, Meng Zhao1, Jia Wang1, Rong Wang1, Yan Zhang1, Dong Zhang1, Jizong Zhao2.   

Abstract

The objective of this study was to elucidate the clinical features, surgical treatment, and outcome of intracranial aneurysms associated with moyamoya disease. We retrospectively reviewed a consecutive cohort of 79 moyamoya disease patients with 98 intracranial aneurysms at Beijing Tiantan Hospital. Clinical features, radiological findings, and outcomes were analyzed. Prevalence of intracranial aneurysms in patients with moyamoya disease was 3.9%. The mean age at diagnosis was 39.0 ± 12.4 years, with 1 peak distribution in patients from 40 to 50 years of age. The ratio of women to men was 1.00:1.03. Familial occurrence was 2.5%. The initial symptom was hemorrhage or ischemia in 56 (70.9%) and 23 patients (30.4%), respectively. Most patients presented with Suzuki stage 3 or 4. Seventy-nine cases had 98 aneurysms. Of the 98 aneurysms, sixteen aneurysms (16.3%) were treated by microsurgery and 7 by endovascular procedures, 13 aneurysms were conservatively managed, the remaining 62 were treated with revascularization alone. After a median nine-month angiographic follow-up, 18 aneurysms received clipped or embolized were completed occlusion, 18 aneurysms received conservative treated or coating were remained stable. Of the remaining 63 aneurysms that were treated with revascularization alone, 59 of 63 aneurysms remained stable, and 2 were obliterated, whereas 1 aneurysm ruptured during the follow-up. Hemorrhage was the most common symptom in intracranial aneurysms associated with moyamoya disease. Revascularization surgery may improve cerebral circulation, decreases hemodynamic stress and prevent the rupture of intracranial aneurysms.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Aneurysms; Clinical features; Moyamoya disease; Outcome; Treatment

Mesh:

Year:  2020        PMID: 33099360     DOI: 10.1016/j.jocn.2020.09.006

Source DB:  PubMed          Journal:  J Clin Neurosci        ISSN: 0967-5868            Impact factor:   1.961


  2 in total

1.  The relationship between hemoglobin and triglycerides in moyamoya disease: A cross-sectional study.

Authors:  Yu Su; Genhua Li; Huihui Zhao; Song Feng; Yan Lu; Jilan Liu; Chao Chen; Feng Jin
Journal:  Front Neurol       Date:  2022-09-08       Impact factor: 4.086

Review 2.  Progression in Moyamoya Disease: Clinical Features, Neuroimaging Evaluation, and Treatment.

Authors:  Xin Zhang; Weiping Xiao; Qing Zhang; Ding Xia; Peng Gao; Jiabin Su; Heng Yang; Xinjie Gao; Wei Ni; Yu Lei; Yuxiang Gu
Journal:  Curr Neuropharmacol       Date:  2022       Impact factor: 7.708

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.